ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 on Perioperative Ramucirumab + FLOT vs. FLOT Alone for Resectable Esophagogastric Adenocarcinoma With High Rate of Signet Cell Component: Final Results of the Multicenter, Randomized Phase II/III Trial
By
ASCO 2022 Conference Coverage
FEATURING
Thorsten Oliver Götze
By
ASCO 2022 Conference Coverage
FEATURING
Thorsten Oliver Götze
17 views
June 14, 2022
Comments 0
Login to view comments.
Click here to Login
GI